Table 2 Clinical pathological characteristics of patients and the correlation between those parameters and overall survival in two risk groups for the Gao et al. cohort. BCLC, Barcelona clinic liver cancer stage
From: A lipid metabolism–based prognostic risk model for HBV–related hepatocellular carcinoma
Variable | High–risk | Low–risk | P |
|---|---|---|---|
n = 123 (77.4%) | n = 36 (22.6%) | ||
Sex | 0.3465 | ||
Male | 101 (82.1%) | 27 (75%) | |
Female | 22 (17.9%) | 9 (25%) | |
Age, years | 0.101 | ||
> 60 | 33 (26.8%) | 15 (41.7%) | |
< =60 | 90 (73.2%) | 21 (58.3%) | |
Tumor number | 0.8322 | ||
> 1 | 32 (26%) | 10 (27.8%) | |
< =1 | 91 (74%) | 26 (72.2%) | |
Tumor size, cm | 0.002239 | ||
> 5.5 | 67 (54.5%) | 9 (25%) | |
< =5.5 | 56 (45.5%) | 27 (75%) | |
Lymph node metastasis | 0.4027 | ||
yes | 1 (0.8%) | 1 (2.8%) | |
no | 122 (99.2%) | 35 (97.2%) | |
BCLC stage | 0.009862 | ||
A | 46 (37.4%) | 22 (61.1%) | |
B | 47 (38.2%) | 5 (13.9%) | |
C | 30 (24.4%) | 9 (25%) | |
TNM stage | 0.3525 | ||
I | 71 (57.7%) | 20 (55.6%) | |
II | 9 (7.3%) | 5 (13.9%) | |
III | 42 (34.1%) | 10 (27.8%) | |
IV | 1 (0.8%) | 1 (2.8%) | |